Ela Pharma

Ela Pharma is a biotechnology company developing innovative drugs designed to address clinical conditions caused by necrosis. The companys drug-development process is based on a new platform for anti-necrosis technology. The prevention and treatment of necrosis is significant to the treatment of numerous pathological conditions and diseases. Ela Pharmas technology is based on a novel approach that directly inhibits an intracellular proteolytic enzyme that plays a critical role in the regulation of necrosis pathways. Ela Pharmas first line of anti-necrosis agents is based on small molecules with structural features suitable for inhibiting a specific cellular target, which were found to significantly inhibit cell necrosis at particularly low concentrations.

Ela Pharma has raised $77K in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include Smart Funding.

Ela Pharma was founded in 2015 by Roi Paul Nathan (Co-founder & CEO), Ilana Nathan (Co-founder).

Ela Pharma operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology.

Ela Pharma is based in Dulchin St 16/6, Tel Aviv-Yafo, Israel, Center District.